BALLERUP, Denmark, Mar 19, 2013/ PRNewswire-AsiaNet/–

LEO Pharma announces a co-creation agreement with the National Psoriasis
Foundation (NPF) in the United States that puts patients at the heart of LEO
Pharma’s innovation process. The move supports the dermatology company’s aim to
develop future care solutions that address patients’ real-life needs.

The co-creation agreement with the US National Psoriasis Foundation aims to
ensure that the needs of people suffering from psoriasis play a central role in
the development of LEO Pharma’s future psoriasis care solutions. Ultimately,
LEO Pharma hopes that its agreement with NPF will pave the way for improved
care solutions that empower people to better manage their psoriasis.

(Logo: http://photos.prnewswire.com/prnh/20130221/595427 )

“Patients have unique insights into their condition. That is why we are
involving patients as active participants in our innovation process. In order
to make a difference to the everyday lives of people with skin conditions, we
want to gain an understanding of their challenges – and work together to find
solutions,” says Kim Kjoeller, Senior Vice President Global Development, LEO
Pharma.

The co-creation agreement is the latest step in LEO Pharma’s approach to
patient care innovation. This approach – where the pharmaceutical industry
joins forces with external partners, such as patient organisations – is gaining
increasing recognition internationally.

“Healthcare research is at a crossroads. Developing new drugs for the many
conditions that still lack a cure or effective treatment is a costly, complex
and high-risk process, leading some pharmaceutical companies to give up on
entire disease areas. LEO Pharma wants to involve patients in shaping future
care solutions,” adds Kim Kjoeller.

Co-creation with plaque psoriasis patients

LEO Pharma’s co-creation with NPF, which begins on 23 March, is based on
the creation of Psoriasis Frontiers, a group of patients who will meet with LEO
Pharma researchers during a series of workshops. The patients will become an
integrated part of LEO Pharma’s innovation process and focus on investigating
needs, testing new care concepts and exploring new solutions. The first task
will be to consider patient needs in relation to new formulations, devices and
packaging.

The Psoriasis Frontiers group will focus both on conventional
pharmaceutical product innovation and on individualised care solutions such as
patient engagement concepts, access models, diagnostic tools and digital
technologies. Psoriasis Frontiers will act as a sounding board, working only
with concepts and not with marketed products. Specific research findings will
be subject to confidentiality; however, partners are committed to publishing
non-competitive findings to the general public.

“National Psoriasis Foundation recognises the need for patient insight into
research and treatment development. This collaboration will allow people living
with the disease to meet face-to-face with scientists creating the cutting-edge
therapies they may use in their everyday life,” says Kathleen Gallant, chair of
the National Psoriasis Foundation Outreach Committee and member of its Board of
Trustees.

“Who better to discuss product innovation and patient care than people
affected by the disease? Hopefully this ‘patient-focused’ research concept
becomes a trend that creates new opportunities.”

About LEO Pharma

LEO Pharma helps people achieve healthy skin. By offering care solutions to
patients in more than 100 countries globally, the company supports people in
managing their skin conditions.

Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted
decades of research and development to delivering products and solutions to
people suffering from skin diseases.

LEO Pharma is headquartered in Denmark and employs around 5,000 people
worldwide.

For more information, visit http://www.leo-pharma.com.

About the National Psoriasis Foundation

The National Psoriasis Foundation is the world’s largest non-profit
organisation serving people with psoriasis and psoriatic arthritis.

Our mission is to find a cure for psoriasis and psoriatic arthritis and to
eliminate their devastating effects through research, advocacy and education.

For more information, call the National Psoriasis Foundation, headquartered
in Portland, Ore., at +1-800-723-9166, or visit http://www.psoriasis.org.
Follow the National Psoriasis Foundation on Facebook
(http://www.facebook.com/national.psoriasis.foundation) and Twitter
(http://www.twitter.com/npf).

SOURCE: LEO Pharma A/S